Who is the CEO of Anlon Healthcare Ltd?
- Answer Field
-
The Chief Executive Officer (CEO) of Anlon Healthcare Limited is Mr. Punit Rasadia.
BAJAJ BROKING
Anlon Healthcare Limited, incorporated in 2013, operates as a chemical manufacturing company with a focus on producing pharmaceutical intermediates and active pharmaceutical ingredients (APIs). Its product range includes high-purity pharmaceutical intermediates used in API production and APIs applied in medicines, nutraceuticals, veterinary products, and personal care formulations. The company follows Indian and international pharmacopeia standards such as IP, BP, EP, JP, and USP, ensuring consistency in its production processes. Over the years, Anlon Healthcare has developed a portfolio of 65 commercialised products, while 28 are at the pilot stage and 49 remain under laboratory testing.
In addition to core manufacturing, the company provides custom solutions for complex chemicals that require higher purity and reduced impurity levels. It has secured approvals for multiple Drug Master Files (DMFs) across global markets and continues to expand filings for additional products. Supported by four laboratories and a qualified team, Anlon Healthcare emphasises testing, analysis, and quality enhancement, contributing to its evolving product pipeline and market presence.
For more details, visit the Anlon Healthcare IPO page.
Details | Information |
IPO Date | August 26, 2025 to August 29, 2025 |
Issue Size | 1,33,00,000 shares (aggregating up to ₹121.03 Cr) |
Price Band | ₹86 to ₹91 per share |
Lot Size | 164 shares |
Listing At | NSE BSE |
Funding capital expenditure requirements for the expansion of the Manufacturing Facility
Full or part repayment and/or pre-payment of certain outstanding secured borrowing (term loan) availed by the Company
Funding the Working capital requirement
General corporate purposes
Event | Date |
---|---|
IPO Open Date | Tue, Aug 26, 2025 |
IPO Close Date | Fri, Aug 29, 2025 |
Tentative Allotment | Mon, Sep 1, 2025 |
Initiation of Refunds | Tue, Sep 2, 2025 |
Credit of Shares to Demat | Tue, Sep 2, 2025 |
Tentative Listing Date | Wed, Sep 3, 2025 |
Cut-off time for UPI mandate confirmation | 5 PM on August 29, 2025 |
₹86 to ₹91 per share
Application | Lots | Shares | Amount |
Retail (Min) | 1 | 164 | ₹14,924 |
Retail (Max) | 13 | 2,132 | ₹1,94,012 |
S-HNI (Min) | 14 | 2,296 | ₹2,08,936 |
S-HNI (Max) | 67 | 10,988 | ₹9,99,908 |
B-HNI (Min) | 68 | 11,152 | ₹10,14,832 |
Log in to Your Trading Account: Access your trading account through your broker’s platform.
Navigate to the IPO Section: Go to the IPO section to view active IPO listings.
Select Anlon Healthcare IPO: Find "Anlon Healthcare IPO" and click on the ‘Apply’ button.
Enter Application Details: Specify the number of lots (minimum lot size: 164 shares) and the bid price within the range of ₹86 to ₹91 per share.
Provide Your UPI ID: Enter your UPI ID for payment authorization. Ensure that sufficient funds are available in your linked account.
Review and Submit: Verify all the details entered before submitting the application. Approve the UPI mandate before 5 PM on August 29, 2025, to complete your application process.
Additional Read- How to Apply for the Anlon Healthcare IPO?
Total Assets: Grew from ₹111.55 crore in FY23 to ₹181.30 crore as of March 2025.
Total income: Reached ₹120.46 crore in FY25.
Profit After Tax (PAT): Stood at ₹20.52 crore for March 2025.
Net Worth: Recorded at ₹80.42 crore in FY25.
Reserves and Surplus: Recorded at ₹40.57 crore (March 2025), growing steadily over the years.
EBITDA: Stood at ₹32.38 crore in March 2025.
The company has demonstrated consistent expansion in its asset base, reflecting its growing financial strength.
Income levels have shown steady progress, supported by business growth across core operations.
Profitability has improved, indicating efficient cost management and operational effectiveness.
Net worth has strengthened, highlighting stability and long-term sustainability.
Reserves and surplus have continued to build over the years, showcasing financial prudence.
Earnings before interest, tax, depreciation, and amortisation have remained healthy, underlining operational efficiency.
The pharmaceutical sector is subject to strict regulatory requirements, and any delay in approvals or changes in compliance standards could affect business operations.
Dependence on international markets and custom chemical manufacturing may expose the company to fluctuations in demand and competition from global players.
Expansion of the manufacturing facility and investment in research can support the development of new pharmaceutical intermediates and APIs.
Ongoing global filings and approvals for Drug Master Files, along with a broad product pipeline, may strengthen the company’s presence across different markets.
KPI | Values |
ROE | 40.45% |
ROCE | 21.93% |
Debt/Equity | 0.73 |
RoNW | 25.51% |
PAT Margin | 17.06% |
EBITDA Margin | 26.88% |
Price to Book Value | 4.51 |
Registrar | Lead Manager(s) |
---|---|
Kfin Technologies Ltd. | Interactive Financial Services Ltd. |
Anlon Healthcare Ltd. 101/102, Silvercoin Complex, Opp.Crystal Mall, Kalawad Road, Rajkot, Gujarat, 360005
Phone: +91 281 2562538
Email: cs@anloncro.com
Website: http://www.anlon.in/
Anlon Healthcare Limited operates in the pharmaceutical manufacturing space with a focus on intermediates and active pharmaceutical ingredients. The company has built a varied portfolio spanning medicines, nutraceuticals, veterinary products, and personal care applications, supported by compliance with both Indian and international pharmacopeia standards. Its operations also include custom chemical solutions designed to meet specific requirements.
The upcoming IPO has been structured to fund expansion of its manufacturing facility, manage borrowings, and address working capital needs. With its existing approvals, product pipeline, and ongoing global filings, the company continues to strengthen its presence in domestic and international markets.
Interested in more opportunities? Check out our Upcoming IPO section for new listings, and don’t forget to check your IPO allotment status for Anlon Healthcare IPO.
Share this article:
No result found
The Chief Executive Officer (CEO) of Anlon Healthcare Limited is Mr. Punit Rasadia.
The IPO will open for subscription on August 26, 2025, and will close on August 29, 2025.
Anlon Healthcare Limited is engaged in manufacturing pharmaceutical intermediates and active pharmaceutical ingredients (APIs) used in medicines, nutraceuticals, veterinary products, and personal care formulations. The company also offers custom manufacturing for complex chemicals. Sustainability of the business model depends on regulatory compliance, product innovation, and demand in domestic and international markets.
The IPO comprises 1,33,00,000 shares, aggregating up to ₹121.03 crore.
‘Pre-apply’ allows investors to place their IPO bid before the official opening date. The application is processed once the IPO opens for subscription.
Investors will receive a confirmation on their registered mobile or email once the application is successfully submitted through their broker or trading platform.
The minimum lot size for retail investors is 164 shares, and applications must be placed in multiples of this lot size.
The tentative allotment date is September 1, 2025.
The registrar to the IPO is Kfin Technologies Ltd.
Based on the available information, there are no publicly reported governance issues or red flags associated with the company’s leadership or board structure. Investors are encouraged to review the company’s Draft Red Herring Prospectus (DRHP) for detailed disclosures.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading